Assembly Biosciences (ASMB) Stock Price, Quote & News

Company Profile

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 509 4583

Website: www.assemblybio.com

Address:

Two Tower Place, 7th Floor, South San Francisco, United States

onemillion2012 Oct. 3 at 5:22 AM

$BCAB very soon.. its time to double up before the stock double.. partnership news very soon now.. Also look at my other looser stocks. $ASMB and the winner of all time shit $BOLT

0 · Reply

ShinnosukeNohara Oct. 1 at 3:35 PM

$ASMB enjoy the party😎

1 · Reply

wonapenny Sep. 29 at 9:47 PM

$ASMB over 1 million shares of ASMB have been sold short 👀

1 · Reply

Chief1960 Sep. 26 at 7:59 PM

$ASMB I think it’s almost time for Gilead science to take over😂👍🏼

1 · Reply

Dachshundtrader Sep. 26 at 6:18 PM

$ASMB – market keeps waiting for that GILD opt-in on 4334… ⏳ The longer the silence, the more it may start to weigh. No update yet — could that uncertainty be holding the stock back? What do you think? 🤔

1 · Reply

Timefortendies77 Sep. 24 at 1:41 PM

$ASMB Monthly results coming soon.....

1 · Reply

JarvisFlow Sep. 24 at 1:00 PM

JMP Securities has adjusted their stance on Assembly Biosciences ( $ASMB ), setting the rating to Market Outperform with a target price of 38.

0 · Reply

deni_mimi Sep. 24 at 12:48 PM

$ASMB

0 · Reply

onemillion2012 Sep. 24 at 7:44 AM

$ASMB year high today.

0 · Reply

ShinnosukeNohara Sep. 22 at 11:27 AM

$ASMB the party just even started.. https://www.boerse-express.com/news/articles/assembly-biosciences-aktie-steuerkurs-optimistisch-826948

1 · Reply

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ATRA CORT

Aug 8, 2025, 4:54 PM EDT - 2 months ago

Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts

Aug 8, 2025, 8:05 AM EDT - 2 months ago

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Aug 8, 2025, 8:00 AM EDT - 2 months ago

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Jul 26, 2025, 3:00 AM EDT - 2 months ago

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Jun 30, 2025, 8:00 AM EDT - 3 months ago

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Jun 25, 2025, 8:00 AM EDT - 3 months ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

May 27, 2025, 4:05 PM EDT - 4 months ago

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

May 8, 2025, 4:05 PM EDT - 5 months ago

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

May 7, 2025, 8:00 AM EDT - 5 months ago

New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

Apr 9, 2025, 2:00 AM EDT - 6 months ago

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Mar 20, 2025, 4:05 PM EDT - 7 months ago

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Feb 26, 2025, 8:00 AM EST - 7 months ago

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Feb 20, 2025, 8:00 AM EST - 8 months ago

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Dec 26, 2024, 8:00 AM EST - 10 months ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

May 22, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

May 8, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Feb 8, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Jan 4, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Nov 10, 2023, 4:05 PM EST - 2 years ago

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 8, 2023, 8:00 AM EST - 2 years ago

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Oct 17, 2023, 7:00 AM EDT - 2 years ago

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

GILD

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Sep 19, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Jul 17, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023

May 23, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

May 4, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

Mar 22, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Jan 17, 2023, 7:00 AM EST - 2 years ago

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Nov 4, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Oct 24, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

Oct 5, 2022, 4:05 PM EDT - 3 years ago

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A.

Aug 9, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Jul 20, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Jun 22, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

Jun 8, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 6, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

May 12, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Mar 10, 2022, 4:05 PM EST - 3 years ago

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

Feb 9, 2022, 8:00 AM EST - 3 years ago

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

Jan 7, 2022, 5:00 PM EST - 4 years ago

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2022, 8:00 AM EST - 4 years ago

Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

onemillion2012 Oct. 3 at 5:22 AM

$BCAB very soon.. its time to double up before the stock double.. partnership news very soon now.. Also look at my other looser stocks. $ASMB and the winner of all time shit $BOLT

0 · Reply

ShinnosukeNohara Oct. 1 at 3:35 PM

$ASMB enjoy the party😎

1 · Reply

wonapenny Sep. 29 at 9:47 PM

$ASMB over 1 million shares of ASMB have been sold short 👀

1 · Reply

Chief1960 Sep. 26 at 7:59 PM

$ASMB I think it’s almost time for Gilead science to take over😂👍🏼

1 · Reply

Dachshundtrader Sep. 26 at 6:18 PM

1 · Reply

Timefortendies77 Sep. 24 at 1:41 PM

$ASMB Monthly results coming soon.....

1 · Reply

JarvisFlow Sep. 24 at 1:00 PM

JMP Securities has adjusted their stance on Assembly Biosciences ( $ASMB ), setting the rating to Market Outperform with a target price of 38.

0 · Reply

deni_mimi Sep. 24 at 12:48 PM

$ASMB

0 · Reply

onemillion2012 Sep. 24 at 7:44 AM

$ASMB year high today.

0 · Reply

ShinnosukeNohara Sep. 22 at 11:27 AM

$ASMB the party just even started.. https://www.boerse-express.com/news/articles/assembly-biosciences-aktie-steuerkurs-optimistisch-826948

1 · Reply

smoothie_maker Sep. 21 at 9:37 PM

$ASMB That volume candle 🌶️ We need to break $29.50 and easy climb to $52. There is no resistance and volume shelves are almost empty all the way to $52

0 · Reply

kpfwutShr43 Sep. 20 at 12:48 PM

$ASMB delicious setup, strong investors, perfect story, waiting for the big bang and double/triple opt in. Nice shaking and manipulation after first run. Now ready for the news drop after their silent filings without pr. Too easy to read the book 🤩🚀

1 · Reply

Poldi2021 Sep. 20 at 6:21 AM

$ASMB Look on the average of traded shares on August 8 ….with in 1,5 month the average is 5 times bigger

0 · Reply

Poldi2021 Sep. 20 at 6:17 AM

$ASMB ohh my god….753k shares traded…this is the hugest volume ever…753k…really interesting days ahead because that volume is Not normal.

1 · Reply

DangerDolan Sep. 19 at 8:04 PM

$ASMB the volume 🧐

0 · Reply

wonapenny Sep. 19 at 8:04 PM

$ASMB holy shit, order for 336K shares at close

0 · Reply

HighReturnStocks Sep. 19 at 6:09 PM

$ASMB looking good glad I averaged up! Holding till we see $35-$40 range minimum

0 · Reply

ShinnosukeNohara Sep. 19 at 5:54 PM

$ASMB 😌

0 · Reply

Poldi2021 Sep. 19 at 5:37 PM

$ASMB ok something reaaalllyyy hot is brewing…huge buyorders…it will be interesting days👏👏👏

0 · Reply

onemillion2012 Sep. 19 at 7:58 AM

$NKTR and i sold this at $22,6 6,000 shares. That's why i am not selling a single share of $ASMB before $50 it can come before you know it. I bought Nektar around 4 months ago at around $10. And i am not selling a single share of $BCAB only adding here. Sitting strong on 550,000 shares. Go Join me in this one.

2 · Reply

Poldi2021 Sep. 18 at 10:13 PM

$ASMB or can you verify what you mentioned? Perhaps I am wrong

0 · Reply

Poldi2021 Sep. 18 at 10:11 PM

$ASMB thought the same but can not be possible. There were about 99k Shares traded today in total

1 · Reply

Market Cap	178.92M
Revenue (ttm)	28.52M
Net Income (ttm)	-40.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140.88%
Debt to Equity Ratio	0.00

Volume	66,700
Avg Vol	142,132
Day's Range	N/A - N/A
Shares Out	7.67M
Stochastic %K	3%
Beta	0.60
Analysts	Strong Sell
Price Target	$38.20